Cargando…

Clinical Pharmacogenetic Models of Treatment Response to Methotrexate Monotherapy in Slovenian and Serbian Rheumatoid Arthritis Patients: Differences in Patient's Management May Preclude Generalization of the Models

Objectives: Methotrexate (MTX) is the first line treatment for rheumatoid arthritis (RA), but nevertheless 30% of patients experience MTX inefficacy. Our aim was to develop a clinical pharmacogenetic model to predict which RA patients will not respond to MTX monotherapy. We also assessed whether thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenko, Barbara, Tomšič, Matija, Jekić, Biljana, Milić, Vera, Dolžan, Vita, Praprotnik, Sonja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788961/
https://www.ncbi.nlm.nih.gov/pubmed/29422864
http://dx.doi.org/10.3389/fphar.2018.00020
_version_ 1783296172318785536
author Jenko, Barbara
Tomšič, Matija
Jekić, Biljana
Milić, Vera
Dolžan, Vita
Praprotnik, Sonja
author_facet Jenko, Barbara
Tomšič, Matija
Jekić, Biljana
Milić, Vera
Dolžan, Vita
Praprotnik, Sonja
author_sort Jenko, Barbara
collection PubMed
description Objectives: Methotrexate (MTX) is the first line treatment for rheumatoid arthritis (RA), but nevertheless 30% of patients experience MTX inefficacy. Our aim was to develop a clinical pharmacogenetic model to predict which RA patients will not respond to MTX monotherapy. We also assessed whether this model can be generalized to other populations by validating it on a group of Serbian RA patients. Methods: In 110 RA Slovenian patients, data on clinical factors and 34 polymorphisms in MTX pathway were analyzed by Least Absolute Shrinkage and Selection Operator (LASSO) penalized regression to select variables associated with the disease activity as measured by Disease Activity Score (DAS28) score after 6 months of MTX monotherapy. A clinical pharmacogenetic index was constructed from penalized regression coefficients with absolute value above 0.05. This index was cross-validated and also independently validated on 133 Serbian RA patients. Results: A clinical pharmacogenetic index for prediction of DAS28 after 6 months of MTX monotherapy in Slovenian RA patients consisted of DAS28 score at diagnosis, presence of erosions, MTX dose, Solute Carrier Family 19 Member 1 (SLC19A1) rs1051266, Solute Carrier Organic Anion Transporter Family Member 1B1 (SLCO1B1) rs2306283, Thymidylate Synthase (TYMS), and Adenosine Monophosphate Deaminase 1 (AMPD1) rs17602729. It correctly classified 69% of Slovenian patients as responders or nonresponders and explained 30% of variability in DAS28 after 6 months of MTX monotherapy. Testing for validity in another population showed that it classified correctly only 22.5% of Serbian RA patients. Conclusions: We developed a clinical pharmacogenetic model for DAS28 after 6 months of MTX monotherapy in Slovenian RA patients by combining clinical and genetic variables. The clinical pharmacogenetic index developed for Slovenian patients did not perform well on Serbian patients, presumably due to the differences in patients' characteristics and clinical management between the two groups.
format Online
Article
Text
id pubmed-5788961
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-57889612018-02-08 Clinical Pharmacogenetic Models of Treatment Response to Methotrexate Monotherapy in Slovenian and Serbian Rheumatoid Arthritis Patients: Differences in Patient's Management May Preclude Generalization of the Models Jenko, Barbara Tomšič, Matija Jekić, Biljana Milić, Vera Dolžan, Vita Praprotnik, Sonja Front Pharmacol Pharmacology Objectives: Methotrexate (MTX) is the first line treatment for rheumatoid arthritis (RA), but nevertheless 30% of patients experience MTX inefficacy. Our aim was to develop a clinical pharmacogenetic model to predict which RA patients will not respond to MTX monotherapy. We also assessed whether this model can be generalized to other populations by validating it on a group of Serbian RA patients. Methods: In 110 RA Slovenian patients, data on clinical factors and 34 polymorphisms in MTX pathway were analyzed by Least Absolute Shrinkage and Selection Operator (LASSO) penalized regression to select variables associated with the disease activity as measured by Disease Activity Score (DAS28) score after 6 months of MTX monotherapy. A clinical pharmacogenetic index was constructed from penalized regression coefficients with absolute value above 0.05. This index was cross-validated and also independently validated on 133 Serbian RA patients. Results: A clinical pharmacogenetic index for prediction of DAS28 after 6 months of MTX monotherapy in Slovenian RA patients consisted of DAS28 score at diagnosis, presence of erosions, MTX dose, Solute Carrier Family 19 Member 1 (SLC19A1) rs1051266, Solute Carrier Organic Anion Transporter Family Member 1B1 (SLCO1B1) rs2306283, Thymidylate Synthase (TYMS), and Adenosine Monophosphate Deaminase 1 (AMPD1) rs17602729. It correctly classified 69% of Slovenian patients as responders or nonresponders and explained 30% of variability in DAS28 after 6 months of MTX monotherapy. Testing for validity in another population showed that it classified correctly only 22.5% of Serbian RA patients. Conclusions: We developed a clinical pharmacogenetic model for DAS28 after 6 months of MTX monotherapy in Slovenian RA patients by combining clinical and genetic variables. The clinical pharmacogenetic index developed for Slovenian patients did not perform well on Serbian patients, presumably due to the differences in patients' characteristics and clinical management between the two groups. Frontiers Media S.A. 2018-01-25 /pmc/articles/PMC5788961/ /pubmed/29422864 http://dx.doi.org/10.3389/fphar.2018.00020 Text en Copyright © 2018 Jenko, Tomšič, Jekić, Milić, Dolžan and Praprotnik. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Jenko, Barbara
Tomšič, Matija
Jekić, Biljana
Milić, Vera
Dolžan, Vita
Praprotnik, Sonja
Clinical Pharmacogenetic Models of Treatment Response to Methotrexate Monotherapy in Slovenian and Serbian Rheumatoid Arthritis Patients: Differences in Patient's Management May Preclude Generalization of the Models
title Clinical Pharmacogenetic Models of Treatment Response to Methotrexate Monotherapy in Slovenian and Serbian Rheumatoid Arthritis Patients: Differences in Patient's Management May Preclude Generalization of the Models
title_full Clinical Pharmacogenetic Models of Treatment Response to Methotrexate Monotherapy in Slovenian and Serbian Rheumatoid Arthritis Patients: Differences in Patient's Management May Preclude Generalization of the Models
title_fullStr Clinical Pharmacogenetic Models of Treatment Response to Methotrexate Monotherapy in Slovenian and Serbian Rheumatoid Arthritis Patients: Differences in Patient's Management May Preclude Generalization of the Models
title_full_unstemmed Clinical Pharmacogenetic Models of Treatment Response to Methotrexate Monotherapy in Slovenian and Serbian Rheumatoid Arthritis Patients: Differences in Patient's Management May Preclude Generalization of the Models
title_short Clinical Pharmacogenetic Models of Treatment Response to Methotrexate Monotherapy in Slovenian and Serbian Rheumatoid Arthritis Patients: Differences in Patient's Management May Preclude Generalization of the Models
title_sort clinical pharmacogenetic models of treatment response to methotrexate monotherapy in slovenian and serbian rheumatoid arthritis patients: differences in patient's management may preclude generalization of the models
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788961/
https://www.ncbi.nlm.nih.gov/pubmed/29422864
http://dx.doi.org/10.3389/fphar.2018.00020
work_keys_str_mv AT jenkobarbara clinicalpharmacogeneticmodelsoftreatmentresponsetomethotrexatemonotherapyinslovenianandserbianrheumatoidarthritispatientsdifferencesinpatientsmanagementmayprecludegeneralizationofthemodels
AT tomsicmatija clinicalpharmacogeneticmodelsoftreatmentresponsetomethotrexatemonotherapyinslovenianandserbianrheumatoidarthritispatientsdifferencesinpatientsmanagementmayprecludegeneralizationofthemodels
AT jekicbiljana clinicalpharmacogeneticmodelsoftreatmentresponsetomethotrexatemonotherapyinslovenianandserbianrheumatoidarthritispatientsdifferencesinpatientsmanagementmayprecludegeneralizationofthemodels
AT milicvera clinicalpharmacogeneticmodelsoftreatmentresponsetomethotrexatemonotherapyinslovenianandserbianrheumatoidarthritispatientsdifferencesinpatientsmanagementmayprecludegeneralizationofthemodels
AT dolzanvita clinicalpharmacogeneticmodelsoftreatmentresponsetomethotrexatemonotherapyinslovenianandserbianrheumatoidarthritispatientsdifferencesinpatientsmanagementmayprecludegeneralizationofthemodels
AT praprotniksonja clinicalpharmacogeneticmodelsoftreatmentresponsetomethotrexatemonotherapyinslovenianandserbianrheumatoidarthritispatientsdifferencesinpatientsmanagementmayprecludegeneralizationofthemodels